PT-141 (Bremelanotide): From Tanning-Peptide Metabolite to FDA-Approved Drug, a Research History

Few research peptides have travelled as far from their origins as bremelanotide. The compound now known by that name began as a laboratory metabolite of a University of Arizona tanning-research peptide, was renamed PT-141 by its developer, and in 2019 became an FDA-approved medicine. That path makes it one of the better-documented melanocortin tools available to researchers. This Vial Post explainer follows the compound through that history, then looks at what the primary literature and the FDA review record say about how it engages melanocortin receptors.

Nothing below is guidance on use in people or animals. The Vial Post covers these compounds strictly as subjects of laboratory and literature research.

The Short Version

• What it is: a cyclic seven-residue analog of alpha-melanocyte-stimulating hormone (alpha-MSH), descended from Melanotan II (Hadley & Dorr 2006).
• What it binds: the melanocortin receptor family. Early developer papers emphasized MC3R and MC4R (Molinoff 2003); the FDA-approved label lists a nonselective potency order of MC1R, MC4R, MC3R, MC5R, MC2R (FDA Vyleesi label 2019).
• Regulatory status: approved by the FDA on June 21, 2019 as Vyleesi, a prescription product for one narrowly defined indication (FDA Vyleesi review 2019). That approval covers the finished drug product only, not research-grade material.

A Timeline of the Compound

1989: Chemists at the University of Arizona publish a family of cyclic lactam fragments of alpha-MSH designed with molecular-dynamics modelling. One of them, Ac-[Nle4, Asp5, D-Phe7, Lys10]-alpha-MSH(4-10)-NH2, is roughly 90 times as potent as the native hormone in a lizard-skin bioassay (Al-Obeidi 1989). That molecule is later known as Melanotan II.

1996: A small pilot phase I study of Melanotan II is published. Investigators record skin-pigmentation changes and also unexpected spontaneous erections, an observation that redirected interest toward central melanocortin signaling (Dorr 1996).

2003: Palatin Technologies scientists describe PT-141, a synthetic alpha-MSH analog that is an agonist at MC3R and MC4R, and report that systemic administration in rats increases c-Fos immunoreactivity in hypothalamic neurons, a marker of neuronal activation (Molinoff 2003).

2004: An intranasal pharmacokinetic study reports a median time to peak concentration of 0.5 hours and a mean half-life of 1.85 to 2.09 hours (Diamond 2004).

2006: A history of melanocortin drug development by Hadley and Dorr identifies PT-141 explicitly as "a new MTII analog" heading into pivotal trials (Hadley & Dorr 2006). A separate placebo-controlled study the same year evaluates the compound in women (Diamond 2006).

2019: The FDA approves bremelanotide injection under the brand Vyleesi (NDA 210557) on June 21, 2019 (FDA Vyleesi review 2019).

2021 to 2024: Cryo-EM structures of the active MC4R-Gs complex appear (Heyder 2021), and cell-culture groups begin using bremelanotide as a receptor probe outside its original field (Suzuki 2024).

Receptor Pharmacology: Two Pictures

Readers comparing sources will notice an apparent contradiction. The 2003 developer paper presents PT-141 as an agonist at MC3R and MC4R, "which are expressed primarily in the central nervous system" (Molinoff 2003). The FDA-approved prescribing information, written after the full development programme, describes bremelanotide as a nonselective agonist whose potency runs MC1R, then MC4R, MC3R, MC5R and MC2R. It also states that binding at MC1R and MC4R is most relevant at the approved exposure, and that MC1R binding on melanocytes leads to melanin expression (FDA Vyleesi label 2019).

The two descriptions are compatible: the early papers focused on the central receptors that explained the behaviour they were studying, while the label reports the full selectivity profile. For anyone designing an experiment, the practical point is that PT-141 should not be treated as an MC4R-selective tool. Activity at MC1R is expected, and controls with subtype-selective antagonists are what make results interpretable.

What the MC4R Structures Show

All five melanocortin receptors are G-protein-coupled receptors that signal mainly through Gs and cyclic AMP. In 2021 Heyder and colleagues solved cryo-EM structures of the human MC4R bound to the Gs protein together with two agonists, NDP-alpha-MSH and setmelanotide (Heyder 2021). A Science paper the same year reported a structure of MC4R in its active state and reported that calcium is required for agonist, but not antagonist, efficacy (Israeli 2021).

Bremelanotide itself was not the ligand in either structure. The structures are still useful context, because bremelanotide shares the core His-Phe-Arg-Trp recognition motif common to melanocortin agonists (Ma 2021), and the papers map the pocket where that motif sits.

A Recent In-Vitro Study

A 2024 paper in Anticancer Research illustrates the compound's current use as a laboratory probe. In human glioblastoma cell lines, bremelanotide lowered expression of survivin, an anti-apoptotic protein, and induced cell death at concentrations the authors reported were not toxic to normal human cells. A melanocortin 3/4 receptor antagonist abolished both effects, as did forced over-expression of survivin (Suzuki 2024). This is a cell-culture result only. Its value for researchers is the experimental design: receptor dependence was demonstrated with an antagonist rather than assumed.

PT-141 Versus Melanotan II

PT-141 grew out of the Melanotan II programme (Hadley & Dorr 2006), so the two are often confused. Melanotan II is the original lactam-bridged Arizona peptide, and it is discussed in pigmentation research because of its MC1R activity (Dorr 1996). PT-141 was carried forward for the central signaling questions raised by that 1996 study. As the FDA label makes clear, though, PT-141 also retains substantial MC1R activity (FDA Vyleesi label 2019). Our separate Melanotan II explainer covers the parent peptide in more depth.

Questions Readers Ask

Are PT-141 and bremelanotide different compounds? No. PT-141 is the development code and bremelanotide is the nonproprietary name of the same cyclic heptapeptide (Molinoff 2003; FDA Vyleesi label 2019).

Is PT-141 selective for MC4R? Not strictly. The FDA label lists MC1R as the most potent target, followed by MC4R (FDA Vyleesi label 2019).

Does FDA approval of Vyleesi cover research peptides sold as "PT-141"? No. The approval applies to a specific finished drug product made by its sponsor under an approved application (FDA Vyleesi review 2019). Material sold for laboratory research is not that product.

Handling in the Lab

Like most research peptides, PT-141 is usually supplied as a lyophilized powder. Standard peptide practice applies: store it cold (commonly -20 degrees C), keep it dry and away from light, prepare solutions only when needed, and avoid repeated freeze-thaw cycles. Supplier and Certificate of Analysis details should be checked batch by batch.

For research and educational use only. This article is not medical advice and does not describe dosing or human use.